DiaMedica Therapeutics Inc.
NASDAQ: DMAC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dietrich John Pauls
- Employees
- 27
- Headquarters
- Minneapolis, United States
- IPO year
- 2012
- Market cap
- $342.7M
- Website
- https://www.diamedica.com
Loading DMAC…
Loading profile data…Frequently asked questions about DMAC
What does DiaMedica Therapeutics Inc. (DMAC) do?
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to sever...
Where does DMAC trade?
DiaMedica Therapeutics Inc. (DMAC) trades on the NASDAQ Capital Market.
What sector is DMAC in?
DiaMedica Therapeutics Inc. (DMAC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of DiaMedica Therapeutics Inc.?
Dietrich John Pauls is the chief executive officer of DiaMedica Therapeutics Inc. (DMAC).
Where is DiaMedica Therapeutics Inc. headquartered?
DiaMedica Therapeutics Inc. is headquartered in United States.
Does DMAC pay a dividend?
DiaMedica Therapeutics Inc. (DMAC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMAC go public?
DiaMedica Therapeutics Inc. (DMAC) completed its initial public offering in 2012.